Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer

Worta J. McCaskill-Stevens, Joseph A. Sparano, Melody Cobleigh, Nicholas J. Robert, Carla Baughman, Donna Neuberg, Eric K. Rowinsky, George W. Sledge

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Studies combining paclitaxel and doxorubicin in the treatment of metastatic breast cancer have shown dose-limiting toxicities and raised questions relating to the risk of cardiac toxicities. This pilot trial evaluates an alternating approach to assess safety and feasibility of paclitaxel alternating with doxorubicin as chemotherapy for recurrent breast cancer. Twelve patients with measurable or evaluable breast cancer who had received no more than one prior chemotherapy (either as adjuvant therapy or therapy for metastatic disease) and no prior anthracycline- or taxane- containing chemotherapy were included. Paclitaxel was administered at 200 mg/2 as a continuous 24-hour intravenous infusion alternating with doxorubicin at 75 mg/m2 intravenously, administered every 21 days for a maximum of 10 cycles of therapy. Objective responses were observed in seven of 12 patients (58%) (three complete responses and four partial responses). Objective responses were seen in lymph node, visceral, soft tissue, and bony sites of metastases. The median duration of response was 9.6 months (range 1.4-20.6). A total number of 102 cycles of therapy were administered with 8 of 12 patients tolerating all 10 cycles (median of 10 cycles per patient, range 2-10). Adverse effects included mild myalgias, arthralgias, and peripheral neuropathies. Cardiac toxicities included asymptomatic sinus tachycardia, sinus bradycardia, and nonspecific T-wave abnormality. One patient experienced left ventricular failure. There were no serious hypersensitivity reactions. Paclitaxel cycles resulted in lower granulocyte nadirs than doxorubicin cycles. There were no significant differences in thrombocytopenia between the two agents. The feasibility of administering paclitaxel and doxorubicin in alternating cycles was demonstrated. This was a well-tolerated regimen with results supportive of safety in administration in an alternating regimen.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalBreast Journal
Volume3
Issue number1
DOIs
StatePublished - 1997

Fingerprint

Paclitaxel
Doxorubicin
Breast Neoplasms
Drug Therapy
Sinus Tachycardia
Therapeutics
Safety
Anthracyclines
Myalgia
Arthralgia
Peripheral Nervous System Diseases
Bradycardia
Granulocytes
Intravenous Infusions
Thrombocytopenia
Hypersensitivity
Lymph Nodes
Neoplasm Metastasis
Cardiotoxicity

Keywords

  • advanced breast disease
  • cardiac toxicity
  • paclitaxel and doxorubicin

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

McCaskill-Stevens, W. J., Sparano, J. A., Cobleigh, M., Robert, N. J., Baughman, C., Neuberg, D., ... Sledge, G. W. (1997). Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. Breast Journal, 3(1), 19-24. https://doi.org/10.1111/j.1524-4741.1997.tb00136.x

Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. / McCaskill-Stevens, Worta J.; Sparano, Joseph A.; Cobleigh, Melody; Robert, Nicholas J.; Baughman, Carla; Neuberg, Donna; Rowinsky, Eric K.; Sledge, George W.

In: Breast Journal, Vol. 3, No. 1, 1997, p. 19-24.

Research output: Contribution to journalArticle

McCaskill-Stevens, WJ, Sparano, JA, Cobleigh, M, Robert, NJ, Baughman, C, Neuberg, D, Rowinsky, EK & Sledge, GW 1997, 'Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer', Breast Journal, vol. 3, no. 1, pp. 19-24. https://doi.org/10.1111/j.1524-4741.1997.tb00136.x
McCaskill-Stevens, Worta J. ; Sparano, Joseph A. ; Cobleigh, Melody ; Robert, Nicholas J. ; Baughman, Carla ; Neuberg, Donna ; Rowinsky, Eric K. ; Sledge, George W. / Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. In: Breast Journal. 1997 ; Vol. 3, No. 1. pp. 19-24.
@article{2b3c1e235b37427797390adbb0f7d5bf,
title = "Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer",
abstract = "Studies combining paclitaxel and doxorubicin in the treatment of metastatic breast cancer have shown dose-limiting toxicities and raised questions relating to the risk of cardiac toxicities. This pilot trial evaluates an alternating approach to assess safety and feasibility of paclitaxel alternating with doxorubicin as chemotherapy for recurrent breast cancer. Twelve patients with measurable or evaluable breast cancer who had received no more than one prior chemotherapy (either as adjuvant therapy or therapy for metastatic disease) and no prior anthracycline- or taxane- containing chemotherapy were included. Paclitaxel was administered at 200 mg/2 as a continuous 24-hour intravenous infusion alternating with doxorubicin at 75 mg/m2 intravenously, administered every 21 days for a maximum of 10 cycles of therapy. Objective responses were observed in seven of 12 patients (58{\%}) (three complete responses and four partial responses). Objective responses were seen in lymph node, visceral, soft tissue, and bony sites of metastases. The median duration of response was 9.6 months (range 1.4-20.6). A total number of 102 cycles of therapy were administered with 8 of 12 patients tolerating all 10 cycles (median of 10 cycles per patient, range 2-10). Adverse effects included mild myalgias, arthralgias, and peripheral neuropathies. Cardiac toxicities included asymptomatic sinus tachycardia, sinus bradycardia, and nonspecific T-wave abnormality. One patient experienced left ventricular failure. There were no serious hypersensitivity reactions. Paclitaxel cycles resulted in lower granulocyte nadirs than doxorubicin cycles. There were no significant differences in thrombocytopenia between the two agents. The feasibility of administering paclitaxel and doxorubicin in alternating cycles was demonstrated. This was a well-tolerated regimen with results supportive of safety in administration in an alternating regimen.",
keywords = "advanced breast disease, cardiac toxicity, paclitaxel and doxorubicin",
author = "McCaskill-Stevens, {Worta J.} and Sparano, {Joseph A.} and Melody Cobleigh and Robert, {Nicholas J.} and Carla Baughman and Donna Neuberg and Rowinsky, {Eric K.} and Sledge, {George W.}",
year = "1997",
doi = "10.1111/j.1524-4741.1997.tb00136.x",
language = "English (US)",
volume = "3",
pages = "19--24",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer

AU - McCaskill-Stevens, Worta J.

AU - Sparano, Joseph A.

AU - Cobleigh, Melody

AU - Robert, Nicholas J.

AU - Baughman, Carla

AU - Neuberg, Donna

AU - Rowinsky, Eric K.

AU - Sledge, George W.

PY - 1997

Y1 - 1997

N2 - Studies combining paclitaxel and doxorubicin in the treatment of metastatic breast cancer have shown dose-limiting toxicities and raised questions relating to the risk of cardiac toxicities. This pilot trial evaluates an alternating approach to assess safety and feasibility of paclitaxel alternating with doxorubicin as chemotherapy for recurrent breast cancer. Twelve patients with measurable or evaluable breast cancer who had received no more than one prior chemotherapy (either as adjuvant therapy or therapy for metastatic disease) and no prior anthracycline- or taxane- containing chemotherapy were included. Paclitaxel was administered at 200 mg/2 as a continuous 24-hour intravenous infusion alternating with doxorubicin at 75 mg/m2 intravenously, administered every 21 days for a maximum of 10 cycles of therapy. Objective responses were observed in seven of 12 patients (58%) (three complete responses and four partial responses). Objective responses were seen in lymph node, visceral, soft tissue, and bony sites of metastases. The median duration of response was 9.6 months (range 1.4-20.6). A total number of 102 cycles of therapy were administered with 8 of 12 patients tolerating all 10 cycles (median of 10 cycles per patient, range 2-10). Adverse effects included mild myalgias, arthralgias, and peripheral neuropathies. Cardiac toxicities included asymptomatic sinus tachycardia, sinus bradycardia, and nonspecific T-wave abnormality. One patient experienced left ventricular failure. There were no serious hypersensitivity reactions. Paclitaxel cycles resulted in lower granulocyte nadirs than doxorubicin cycles. There were no significant differences in thrombocytopenia between the two agents. The feasibility of administering paclitaxel and doxorubicin in alternating cycles was demonstrated. This was a well-tolerated regimen with results supportive of safety in administration in an alternating regimen.

AB - Studies combining paclitaxel and doxorubicin in the treatment of metastatic breast cancer have shown dose-limiting toxicities and raised questions relating to the risk of cardiac toxicities. This pilot trial evaluates an alternating approach to assess safety and feasibility of paclitaxel alternating with doxorubicin as chemotherapy for recurrent breast cancer. Twelve patients with measurable or evaluable breast cancer who had received no more than one prior chemotherapy (either as adjuvant therapy or therapy for metastatic disease) and no prior anthracycline- or taxane- containing chemotherapy were included. Paclitaxel was administered at 200 mg/2 as a continuous 24-hour intravenous infusion alternating with doxorubicin at 75 mg/m2 intravenously, administered every 21 days for a maximum of 10 cycles of therapy. Objective responses were observed in seven of 12 patients (58%) (three complete responses and four partial responses). Objective responses were seen in lymph node, visceral, soft tissue, and bony sites of metastases. The median duration of response was 9.6 months (range 1.4-20.6). A total number of 102 cycles of therapy were administered with 8 of 12 patients tolerating all 10 cycles (median of 10 cycles per patient, range 2-10). Adverse effects included mild myalgias, arthralgias, and peripheral neuropathies. Cardiac toxicities included asymptomatic sinus tachycardia, sinus bradycardia, and nonspecific T-wave abnormality. One patient experienced left ventricular failure. There were no serious hypersensitivity reactions. Paclitaxel cycles resulted in lower granulocyte nadirs than doxorubicin cycles. There were no significant differences in thrombocytopenia between the two agents. The feasibility of administering paclitaxel and doxorubicin in alternating cycles was demonstrated. This was a well-tolerated regimen with results supportive of safety in administration in an alternating regimen.

KW - advanced breast disease

KW - cardiac toxicity

KW - paclitaxel and doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=0030967624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030967624&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4741.1997.tb00136.x

DO - 10.1111/j.1524-4741.1997.tb00136.x

M3 - Article

AN - SCOPUS:0030967624

VL - 3

SP - 19

EP - 24

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 1

ER -